Information Provided By: 
Fly News Breaks for February 25, 2019
ATRS
Feb 25, 2019 | 08:20 EDT
Cowen analyst Bill Maughan initiated Antares Pharma with an Outperform rating as he sees it as the pre-eminent auto-injector developer, while almost near the break-even point due to its meaningful partnerships. He said its durable revenue base has created a self-sustaining company. Maughan has a $7 price target on Antares Pharma shares.
News For ATRS From the Last 2 Days
There are no results for your query ATRS
